Maxwell Skor

have you seen any change in the severity mix or overall profile of the bronchiectasis patients on treatment through the early stages of the launch?

how do you expect pulmonologists to navigate payer requirements around ruling out COPD or asthma as the primary driver of symptoms

how would you characterize BRINSUPRI's performance to date relative to the launch analogs you provided?

I was just hoping you could share any early operational and clinical insights into that experience?

Could you remind me the rationale for measuring PVR versus baseline and how we should think about the potential placebo rate?